With multiple modalities of care for cancer patients, oncology treatment decision-making has always been complex, but accelerating innovation is driving exponential growth in treatment complexity. Genomic advances continue to enable development of new targeted therapies and immunotherapy agents have demonstrated promising outcome improvements across multiple tumor types. These new treatments are being overlaid upon the more traditional chemotherapies and hormone therapies, producing a wide variety of possible treatment pathways.
The pace of new drug development continues to accelerate: there are more than 650 cancer treatment candidates in late-stage clinical...